Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posts Tagged ‘Diabetes mellitus type 2’

Developments in the Genomics and Proteomics of Type 2 Diabetes Mellitus and Treatment Targets

Posted in Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Diabetes Mellitus, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Genome Biology, Genomic Testing: Methodology for Diagnosis, Inferential analysis, Metabolomics, Molecular Genetics & Pharmaceutical, Nephrology, Pharmaceutical Analytics, Pharmacologic toxicities, Proteomics, Systemic Inflammatory Response Related Disorders, Translational Effectiveness, Translational Science, tagged cardiovascular complications, Diabetes mellitus type 2, gene expression, Genome Research, genomic drug development, Heart Failure, New England Journal of Medicine, Obesity, Personalized medicine, prediabetes, selective inhibitors, stage 3 & 4 renal disease on December 8, 2013| Leave a Comment »

Larry H Bernstein, MD, FCAP, Reviewer and Curator

http://pharmaceuticalintelligence.com/2013-12-08/larryhbern/Developments-in-the-Genomics-and-Proteomics-of-Type-2-Diabetes-Mellitus-and-Treatment-Targets

Researchers Solve a Mystery about Type 2 Diabetes Drug

AB SCIEX TripleTOF® and QTRAP® technologies support breakthrough medical study.

Published: Friday, November 22, 2013

Researchers from St. Vincent’s Institute of Medical Research in Melbourne, Australia, in collaboration with researchers at McMaster University in Canada, are reportedly the first to discover how the type 2 diabetes drug metformin actually works, providing a molecular understanding that could lead to the development of more effective therapies. Mass spectrometry technologies from AB SCIEX played a critical role in the analysis that led to this breakthrough finding.  The research is published in this month’s issue of the journal Nature Medicine.

Doctors have known for decades that metformin helps treat type 2 diabetes.  However, questions had lingered for more than 50 years whether this drug, which is available as a generic drug,

• worked to lower blood glucose in patients by directly working on the glucose.

People with type 2 diabetes have high blood sugar levels and have trouble converting sugar in their blood into energy because of low levels of insulin. For treating this condition, metformin is considered the most widely prescribed anti-diabetic drug in the world.

Until now, no one had been able to explain adequately how this drug lowers blood sugar. According to this new study, the drug works by reducing harmful fat in the liver. People who take metformin reportedly often have a fatty liver, which is frequently caused by obesity.

“Fat is likely a key trigger for pre-diabetes in humans,” said Professor Bruce Kemp, PhD, the Head of Protein Chemistry and Metabolism at St. Vincent’s Institute of Medical Research.  “Our study indicates that

• metformin doesn’t directly reduce sugar metabolism, as previously suspected, but instead
•  reduces fat in the liver, which in turn allows insulin to work effectively.”

The breakthrough in pinning down how the drug functions began with the researchers making

• genetic mutations to the genes of two enzymes, ACC1 and ACC2,

in mice, so they could no longer be controlled.  What happened next surprised the researchers:

• the mice didn’t get fat as expected,

but Associate Professor Gregory Steinberg, PhD at McMaster University noticed that

• the mice had fatty livers and a pre-diabetic condition.

Then the researchers put the mice on

• a high fat diet and they became fat, while metformin
• did not lower the blood sugar levels of the mutant mice.

The findings are expected to help researchers better directly target the condition, which affects over 100 million people around the world, according to published reports. It is also believed that with the mystery of metformin solved, the application of the drug could go beyond just diabetes and potentially be used to treat other medical conditions.

“AB SCIEX mass spectrometry solutions help researchers explore big questions and conduct breakthrough studies, such as this remarkable type 2 diabetes study,” said Rainer Blair, President of AB SCIEX.   “In order to understand disease at the molecular level, researchers need the sensitive detection and reproducible quantitation provided by AB SCIEX tools. We enable the research community to solve biological mysteries and rethink the possibilities to transform health.”

For the research conducted by the Australian and Canadian researchers, the analysis at the molecular level was optimized on AB SCIEX instrumentation, including the AB SCIEX TripleTOF® 5600 and the AB SCIEX QTRAP® 5500 system.

The TripleTOF system, with its high-speed, high-quality MS/MS capabilities,

• was used for the discovery of key proteins and phosphopeptides.

The QTRAP system, with its high sensitivity MRM (multiple reaction monitoring) capabilities,

• was used for quantitation of metabolites, including nucleotides and malonyl-CoA. 

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

D de Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, ….,and GM Chertow, for the BEACON Trial Investigators

November 9, 2013  http://dx.doi.org/10.1056/NEJMoa1306033

http://www.nejm.org/doi/full/10.1056/NEJMoa1306033

Type 2 diabetes mellitus is the most important cause of progressive chronic kidney disease in the developed and developing worlds. Various therapeutic approaches to slow progression, including

• restriction of dietary protein,
• glycemic control, and
• control of hypertension,

have yielded mixed results.1-3 Several randomized clinical trials have shown that

• inhibitors of the renin–angiotensin–aldosterone system significantly reduce the risk of progression,4-6 although
• the residual risk remains high.7

None of the new agents tested during the past decade have proved effective in late-stage clinical trials.8-12

Oxidative stress and impaired antioxidant capacity intensify 

• with the progression of chronic kidney disease.13

In animals with chronic kidney disease,

• oxidative stress and inflammation
• are associated with impaired activity of the nuclear 1 factor (erythroid-derived 2)–related factor 2 (Nrf2) transcription factor.

The synthetic triterpenoid bardoxolone methyl and its analogues are the most potent known activators of the Nrf2 pathway. Studies involving humans,14 including persons with type 2 diabetes mellitus and stage 3b or 4 chronic kidney disease, have shown that

• bardoxolone methyl can reduce the serum creatinine concentration for up to 52 weeks.15

We designed the Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal Events (BEACON) trial to test the hypothesis that

• treatment with bardoxolone methyl reduces the risk of end-stage renal disease (ESRD) or death from cardiovascular causes

among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Methods

Study Design and Oversight

The BEACON trial was a phase 3, randomized, double-blind, parallel-group, international, multicenter trial of

• once-daily administration of bardoxolone methyl (at a dose of 20 mg in an amorphous spray-dried dispersion formulation), as compared with placebo.

Participants were receiving background conventional therapy that included 

• inhibitors of the renin–angiotensin–aldosterone system,
• insulin or other hypoglycemic agents, and, when appropriate,
• other cardiovascular medications.

The trial design and the characteristics of the trial participants at baseline have been described previously.16,17

Reata Pharmaceuticals sponsored the trial. The trial was jointly designed by employees of the sponsor and the academic investigators who were members of the steering committee. The steering committee, which was led by the academic investigators and included members who were employees of the sponsor, supervised the trial design and operation. An independent data and safety monitoring committee reviewed interim safety data every 90 days or on an ad hoc basis on request. The sponsor collected the trial data and transferred them to independent statisticians at Statistics Collaborative. The sponsor also contracted a second independent statistical group (Axio Research) to support the independent data and safety monitoring committee. The trial protocol was approved by the institutional review board at each participating study site. The protocol and amendments are available with the full text of this article at NEJM.org. The steering committee takes full responsibility for the integrity of the data and the interpretation of the trial results and for the fidelity of the study to the protocol. The first and last authors wrote the first draft of the manuscript. All the members of the steering committee made the decision to submit the manuscript for publication.

Study Population

Briefly, we included adults with 

• type 2 diabetes mellitus and
• an estimated glomerular filtration rate (GFR) of 15 to <30 ml per minute per 1.73 m2 BSA.

1. Persons with poor glycemic control,
2. uncontrolled hypertension, or
3. a recent cardiovascular event (≤12 weeks before randomization) or
4. New York Heart Association class III or IV heart failure were excluded.

Additional inclusion and exclusion criteria are listed in Table S1 in the Supplementary Appendix, available at NEJM.org. All the patients provided written informed consent.

Randomization and Intervention

 Randomization was stratified according to study site with the use of variable-sized blocks. The steering committee, sponsor, investigators, and trial participants were unaware of the group assignments. After randomization,

• patients received either bardoxolone methyl or placebo.

The prescription of all other medications was at the discretion of treating physicians, who were encouraged to adhere to published clinical-practice guidelines. Patients underwent event ascertainment and laboratory testing according to the study schema shown in Figure S1 in the Supplementary Appendix. Ambulatory blood-pressure monitoring was performed in a substudy that included 174 patients (8%).

The statistical analysis plan defined the study period as the number of days from randomization to a common study-termination date. In the case of patients who were still receiving the study drug on the termination date, data on vital events were collected for an additional 30 days.

Outcomes

 The primary composite outcome was ESRD or death from cardiovascular causes. We defined ESRD as

• the need for maintenance dialysis for 12 weeks or more or kidney transplantation.

If a patient died before undergoing dialysis for 12 weeks, the independent events-adjudication committee adjudicated whether the need for dialysis represented ESRD or acute renal failure. Patients who declined dialysis and who subsequently died were categorized as having had ESRD. All ESRD events were adjudicated. Death from cardiovascular causes was defined as death due to either cardiovascular or unknown causes.

The trial had three prespecified secondary outcomes —

1. first, the change in estimated GFR as calculated with the use of the four-variable Modification of Diet in Renal Disease study equation, with serum creatinine levels calibrated to an isotope-dilution standard for mass spectrometry;
2. second, hospitalization for heart failure or death due to heart failure; and
3. third, a composite outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death from cardiovascular causes.

The events-adjudication committee, whose members were unaware of the study assignments, evaluated whether

• ESRD events,
• cardiovascular events,
• neurologic events, and
• deaths

met the prespecified criteria for primary and secondary outcomes (described in detail in the Supplementary Appendix).

Statistical Analysis

We calculated that we needed to enroll 2000 patients on the basis of the following assumptions:

• a two-sided type I error rate of 5%, an event rate of 24% for the primary composite outcome in the placebo group during the first 2 years of the study,
• a hazard ratio of 0.68 (bardoxolone methyl vs. placebo) for the primary composite outcome,
• discontinuation of the study drug by 13.5% of the patients in the bardoxolone methyl group each year, and
• a 2.5% annual loss to follow-up in each group.

Under these assumptions, if 300 patients had a primary composite outcome, the statistical power would be 85%.

We collected and analyzed all outcome data in accordance with the intention-to-treat principle. We calculated Kaplan–Meier product-limit estimates of

• the cumulative incidence of the primary composite outcome.

We computed hazard ratios and 95% confidence intervals with the use of Cox proportional-hazards regression models with adjustment for

• the baseline estimated GFR and urinary albumin-to-creatinine ratio.

We performed analogous analyses for secondary time-to-event outcomes. Given the abundance of early adverse events, we also report discrete cumulative incidences at 4 weeks and 52 weeks.

For longitudinal analyses of estimated GFR, we performed mixed-effects regression analyses using

1. study group,
2. time,
3. the interaction of study group with time,
4. estimated GFR at baseline,
5. the interaction of baseline estimated GFR with time, and
6. urinary albumin-to-creatinine ratio as covariates, and
7. we compared the means between the bardoxolone methyl group and the placebo group.

We adopted similar approaches when examining the effects of treatment on other continuous measures assessed at multiple visits. Since the between-group difference in the primary composite outcome was not significant,

secondary and other outcomes with P values of less than 0.05 were considered to be nominally significant.

Statistical analyses were performed with the use of SAS software, version 9.3 (SAS Institute). Additional details of the statistical analysis are provided in the Supplementary Appendix.

Results

Patients

From June 2011 through September 2012, a total of 2185 patients underwent randomization, including 1545 (71%) in the United States, 334 (15%) in the European Union, 133 (6%) in Australia, 87 (4%) in Canada, 46 (2%) in Israel, and 40 (2%) in Mexico. Figure S2 in the Supplementary Appendix shows the disposition of the study participants.

As shown in Table 1Table 1Baseline Characteristics of the Patients in the Intention-to-Treat Population., the patients were diverse with respect to age, sex, race or ethnic group, and region of origin;

• diabetic retinopathy and neuropathy were common conditions among the patients,
• as was overt cardiovascular disease.

See Table S2 in the Supplementary Appendix for a more detailed description of the characteristics of the patients at baseline; Figure S3 in the Supplementary Appendix shows the distribution of baseline estimated GFR and urinary albumin-to-creatinine ratio.

Drug Exposure

The median duration of exposure to the study drug was 7 months (interquartile range, 3 to 11) among patients randomly assigned to bardoxolone methyl and

• 8 months (interquartile range, 5 to 11) among those randomly assigned to placebo.

Figure S4 in the Supplementary Appendix shows the time to discontinuation of the study drug. Table S3 in the Supplementary Appendix shows the reasons that patients discontinued the study drug and the reasons that patients discontinued the study.

• The median duration of follow-up was 9 months in both groups.

Outcomes

Primary Composite Outcome

A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone methyl and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone methyl group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P=0.92) (Figure 1AFigure 1Kaplan–Meier Plots of the Time to the First Event of the Primary Outcome and Its Components.).

• Death from cardiovascular causes occurred in 27 patients randomly assigned to bardoxolone methyl and in 19 randomly assigned to placebo (hazard ratio, 1.44; 95% CI, 0.80 to 2.59; P=0.23) (Figure 1B).
• ESRD developed in 43 patients randomly assigned to bardoxolone methyl and in 51 randomly assigned to placebo (hazard ratio, 0.82; 95% CI, 0.55 to 1.24; P=0.35) (Figure 1C).

One patient in each group died from cardiovascular causes after the development of ESRD. The mean (±SD) estimated GFR

• before the development of ESRD was 18.1±8.3 ml per minute per 1.73 m^2 in the bardoxolone methyl group and
• 14.9±4.0 ml per minute per 1.73 m2 in the placebo group.

Secondary Outcomes

During the study period, 96 patients in the bardoxolone methyl group had heart-failure events (93 patients with at least one hospitalization due to heart failure and 3 patients who died from heart failure without hospitalization),

• as compared with 55 in the placebo group (55 patients with at least one hospitalization due to heart failure and
• no patients who died from heart failure without hospitalization) (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P<0.001) (Figure 2AFigure 2Kaplan–Meier Plots of the Time to the First Event of the Discrete Secondary Outcomes.).

A total of 139 patients in the bardoxolone methyl group, as compared with 86 in the placebo group, had

• a composite outcome event of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death from cardiovascular causes (hazard ratio, 1.71; 95% CI, 1.31 to 2.24; P<0.001) (Figure 2B).

Incidences of Composite Outcomes and Rates of Death from Any Cause

The cumulative incidences of the primary composite outcome and of the two secondary composite outcomes at 4 weeks and at 52 weeks are shown in Table S4 in the Supplementary Appendix. The rates of death from any cause are shown in Figure S5 in the Supplementary Appendix. From the time of randomization to the end of follow-up, 75 patients died: 44 patients in the bardoxolone methyl group and 31 in the placebo group (hazard ratio, 1.47; 95% CI, 0.93 to 2.32; P=0.10). The causes of death are listed in Table S5 in the Supplementary Appendix.

Estimated GFR

Patients randomly assigned to placebo had a significant mean decline in the estimated GFR from the baseline value (−0.9 ml per minute per 1.73 m2; 95% CI, −1.2 to −0.5), whereas those randomly assigned to bardoxolone methyl had a significant mean increase from the baseline value (5.5 ml per minute per 1.73 m2; 95% CI, 5.2 to 5.9). The difference between the two groups was 6.4 ml per minute per 1.73 m2 (95% CI, 5.9 to 6.9; P<0.001) (Figure 3AFigure 3Estimated Glomerular Filtration Rate (GFR), Body Weight, and Urinary Albumin-to-Creatinine Ratio.).

Physiological Variables

Physiological variables are shown in Table S6 in the Supplementary Appendix. The mean body weight remained stable in the placebo group

• but declined steadily and substantially in the bardoxolone methyl group (Figure 3B).

There was a significantly smaller decrease from baseline in mean systolic blood pressure in the bardoxolone methyl group than in the placebo group (between-group difference, 1.5 mm Hg [95% CI, 0.5 to 2.5]), and

• the mean diastolic blood pressure increased from baseline in the bardoxolone methyl group whereas it decreased in the placebo group (between-group difference, 2.1 mm Hg [95% CI, 1.6 to 2.6]).

Blood-pressure results from the substudy in which ambulatory blood-pressure monitoring was performed were similar in direction but were more pronounced (between-group difference of 7.9 mm Hg [95% CI, 3.8 to 12.0] in systolic blood pressure and 3.2 mm Hg [95% CI, 1.3 to 5.2] in diastolic blood pressure).

• Heart rate also increased significantly in the bardoxolone methyl group, as compared with the placebo group (between-group difference, 3.8 beats per minute; 95% CI, 3.2 to 4.4).

Other Laboratory Variables

Data on laboratory variables are shown in Table S7 in the Supplementary Appendix.

• The urinary albumin-to-creatinine ratio increased significantly in the bardoxolone methyl group, as compared with the placebo group (Figure 3C).
• Serum magnesium, albumin, hemoglobin, and glycated hemoglobin levels decreased significantly in the bardoxolone methyl group, as compared with the placebo group.
• The level of B-type natriuretic peptide increased significantly by week 24 in the bardoxolone methyl group, as compared with the placebo group.

Adverse Events

The rates of serious adverse events are summarized in Table 2Table 2Most Commonly Reported Serious Adverse Events in the Intention-to-Treat Population. Serious adverse events occurred more frequently in the bardoxolone methyl group than in the placebo group (717 events in 363 patients vs. 557 events in 295 patients). There were 11 neoplastic events in the bardoxolone methyl group and 10 in placebo group. The most commonly reported adverse events are summarized in Table S8 in the Supplementary Appendix.

Discussion

The current trial was designed to determine whether bardoxolone methyl, an activator of the cytoprotective Nrf2 pathway, would reduce the risk of ESRD

• among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease
• who were receiving guideline-based conventional therapy.

The trial was terminated early because of safety concerns, driven primarily by an increase in cardiovascular events in the bardoxolone methyl group. Bardoxolone methyl did not lower the risk of ESRD or of death from cardiovascular causes, although too few events occurred during the trial to reliably determine the true effect of the drug on the primary composite outcome.

Given the truncated duration of the trial and the number of adjudicated events (46% of the events planned), and assuming no change in any of the original assumptions, we estimated the conditional power of the trial to be less than 40%. Although patients treated with bardoxolone methyl had a significant increase in the estimated GFR, as compared with those who received placebo,

• there was a significantly higher incidence of heart failure and of the composite outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death from cardiovascular causes in the bardoxolone methyl group.
• There were numerically more deaths from any cause among patients treated with bardoxolone methyl than among those in the placebo group.

Bardoxolone methyl is among the first orally available antioxidant Nrf2 activators. A small previous study showed that bardoxolone methyl

• reduced inflammation and oxidative stress13 and
• induced a decline in the serum creatinine level.

In the 52-Week Bardoxolone Methyl Treatment: Renal Function in CKD/Type 2 Diabetes (BEAM) trial,15 227 patients with type 2 diabetes mellitus and an estimated GFR of 20 to 45 ml per minute per 1.73 m2

• had a significant increase in the estimated GFR (mean change, 8.2 to 11.4 ml per minute per 1.73 m2, depending on the dose group)
• that was sustained over the entire trial period.

Muscle spasms and hypomagnesemia were the most common adverse events;

• there was no increase in the rate of heart failure or other cardiovascular events.

The current trial was designed to determine whether the change in estimated GFR that we anticipated on the basis of the results of the BEAM trial would translate into a slower progression toward ESRD. Although in the current trial ESRD developed in fewer patients in the bardoxolone methyl group than in the placebo group, the early termination of the trial precludes conclusion of the effect on ESRD events.

The mechanism linking bardoxolone methyl to heart failure is unknown. Since an excess in heart-failure events was unanticipated, echocardiography was not performed routinely before randomization. Although weight declined significantly in the bardoxolone methyl group, we were unable to determine whether there was loss of body fat, intracellular (skeletal muscle) water, or extracellular (interstitial) water.

The fall in serum albumin and hemoglobin levels may reflect hemodilution caused by fluid retention.

Bardoxolone methyl also increased blood pressure.

An increase in preload due to volume expansion and an increase in afterload (as reflected by increased blood pressure),

• coupled with an increase in heart rate,
• constitute a potentially potent combination of factors that are likely to precipitate heart failure in an at-risk population.

The rise in the level of B-type natriuretic peptide with bardoxolone methyl

• is consistent with an increase in left ventricular wall stress owing to one or more of these mediators or to unrecognized factors such as
• impaired diastolic filling of the left ventricle.

After recognizing the initial increase in heart-failure events, the independent data and safety monitoring committee tried to identify

• clinical characteristics that were associated with patients who were at elevated risk for heart failure
• after the initiation of bardoxolone methyl therapy (with the possibility of modifying eligibility criteria or otherwise altering the trial),

but the committee was unable to do so. Other, noncardiovascular adverse events were also observed more frequently among patients exposed to bardoxolone methyl than among those who received placebo. Whether the effects of Nrf2 activation, or one or more counterregulatory responses, rendered this particular population vulnerable, is unknown. Zoja et al.18 found an increase in albuminuria and blood pressure along with weight loss in Zucker diabetic fatty rats treated with an analogue of bardoxolone methyl; these effects were not observed in other studies in Zucker diabetic fatty rats or other rodent models or in 1-year toxicologic studies in monkeys.19-21

Why were these adverse effects identified in the current trial and not in the BEAM trial?

1. First, the number of patient-months of drug exposure in the current trial was roughly 10 times that in the BEAM trial.
2. Second, the population in the present trial had more severe chronic kidney disease than did the population in the BEAM trial.

Observational studies have shown significantly higher rates of death and cardiovascular events, including heart failure,

• among patients with stage 4 chronic kidney disease than among patients with stage 3 chronic kidney disease.22

Finally, our trial used an amorphous spray-dried dispersion formulation of bardoxolone methyl at a fixed dose rather than at an adjusted dose. We chose the 20-mg dose and the specific formulation used in the BEACON trial

1. on the basis of four phase 2 studies of chronic kidney disease (three studies used the crystalline formulation, and one used the amorphous formulation),
2. a crossover pharmacokinetics study involving humans that used both formulations, and
3. several studies in animals that used both formulations (Meyer C: personal communication),

to provide an activity and safety profile that was similar to that observed with 75 mg of the crystalline formulation, which was one of the dose levels tested in the BEAM trial.

In conclusion, among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of the primary composite outcome of ESRD or death from cardiovascular causes. Significantly increased risks of heart failure and of the composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death from cardiovascular causes) prompted termination of the trial.

Alto, CA 93034, or at gchertow@stanford.edu.

Investigators in the Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal Events (BEACON) trial are listed in the Supplementary Appendix, available at NEJM.org.

Table 1. Baseline Characteristics of the Patients in the Intention-to-Treat Population.

Fig 1. Kaplan–Meier Plots of the Time to the First Event of the Primary Outcome and Its Components.

Fig 2. Kaplan–Meier Plots of the Time to the First Event of the Discrete Secondary Outcomes

Fig 3.  Estimated Glomerular Filtration Rate (GFR), Body Weight, and Urinary Albumin-to-Creatinine Ratio

Table 2  Most Commonly Reported Serious Adverse Events in the Intention-to-Treat Population

References

    1  Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-884

    2  The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572

    3  Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-1179

    4  Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869

    5 Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860

   6  Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878

    7  Heerspink HJ, de Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011;8:392-402

    8  Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032

    9   Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-2213

    10   Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23:123-130

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

Linda F. Fried, M.D., M.P.H., Nicholas Emanuele, M.D., Jane H. Zhang, Ph.D., Mary Brophy, M.D., Todd A. Conner, Pharm.D., William Duckworth, M.D., David J. Leehey, M.D., Peter A. McCullough, M.D., M.P.H., Theresa O’Connor, Ph.D., Paul M. Palevsky, M.D., Robert F. Reilly, M.D., Stephen L. Seliger, M.D., Stuart R. Warren, J.D., Pharm.D., Suzanne Watnick, M.D., Peter Peduzzi, Ph.D., and Peter Guarino, M.P.H., Ph.D. for the VA NEPHRON-D Investigators

N Engl J Med 2013; 369:1892-1903November 14, 2013DOI: 10.1056/NEJMoa1303154

Share:

Background

Combination therapy with angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain.

Methods

We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m2 of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥30 ml per minute per 1.73 m2 if the initial estimated GFR was ≥60 ml per minute per 1.73 m2 or a decline of ≥50% if the initial estimated GFR was <60 ml per minute per 1.73 m2), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury.

Results

The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001).

Conclusions

Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.)

A complete list of investigators in the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) study is provided in the Supplementary Appendix, available at NEJM.org.

Figure 1  Kaplan–Meier Plot of Cumulative Probabilities of the Primary and Secondary End Points and Death.

Figure 2 Kaplan–Meier Plot of Cumulative Probabilities of Acute Kidney Injury and Hyperkalemia

The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade?

Nov 14, 2013       de Zeeuw D.  (Editorial)

 N Engl J Med 2013; 369:1960-1962

Treatment aimed at multiple risk factors and specific markers such as glucose level, blood pressure, body weight, cholesterol levels, and albuminuria has been the main focus to slow cardiovascular and renal risk among patients with diabetes. Among the agents used, those that interrupt the renin–angiotensin–aldosterone system (RAAS) have shown protection that extends beyond decreasing blood pressure. In part, these additional effects may be explained by a decrease in albuminuria.1 Therefore, angiotensin-converting–enzyme (ACE) inhibitors and angiotensin II–receptor blockers (ARBs) have become first-choice drugs in patients with diabetes. Despite some success, the residual cardiovascular and renal risk among patients with diabetes remains

Diabetes: Mouse Studies Point to Kinase as Treatment Target

Published: Nov 24, 2013
By Kristina Fiore, Staff Writer, MedPage Today

Targeting a pathway that plays a major role in both hepatic glucose production and insulin sensitivity may eventually help treat type 2 diabetes, researchers reported.
In a series of experiments in mice, researchers found that inhibition of the kinase CaMKII — or even some of its downstream components — lowered blood glucose and insulin levels, Ira Tabas, MD, PhD, of Columbia University Medical Center in New York City, and colleagues reported online in Cell Metabolism.
The pathway is activated by glucagon signaling in the liver, and appears to have roles in both insulin resistance as well as hepatic glucose production in the liver.
In an earlier study, Tabas and colleagues showed that inhibiting the CaMKII pathway lowered hepatic glucose production by suppressing p38-mediated FoxO1 nuclear localization.
In the current study, they found CaMKII inhibition suppresses levels of the pseudo-kinase TRB3 to improve Akt-phosphorylation, thereby improving insulin sensitivity.
Thus this single pathway targets “two cardinal features of type 2 diabetes — hyperglycemia and defective insulin signaling,” the researchers wrote.
“When we realized we had one common pathway that was responsible for these two disparate processes that, in essence, comprises all of type 2 diabetes, we though it would be an ideal target for new drug therapy,” Tabas told MedPage Today.
Tabas and colleagues conducted several experiments to evaluate the CaMKII pathway.
In one experiment in obese mice, they found that

• no matter how CaMKII was knocked out, it led to lower blood glucose levels and lower fasting plasma insulin levels in response to a glucose challenge.

The improvements also occurred

• when they knocked out downstream processes, including p38 and MAPK-activating protein kinase 2 (MK2).

“Thus liver p38 and MK2, like CaMKII, play an important role in the development of hyperglycemia and hyperinsulinemia in obese mice,” they wrote.
In further analyses, the researchers discovered

• deleting or inhibiting any of these three elements ultimately improved insulin-induced Akt-phosphorylation in obese mice —
• an important part of improving insulin sensitivity.

And unlike the effects on hepatic glucose production, these changes didn’t occur through effects on FoxO1.
Instead, inhibiting the CaMKII pathway suppressed levels of the pseudo-kinase TRB3, which likely occurred because of suppression of ATF4 —

• all of which led to an increase in Akt-phosphorylation and insulin sensitivity.

Indeed, when mice were made to overexpress TRB3, the improvement in phosphorylation disappeared, “indicating that

• the suppression of TRB3 by CaMKII deficiency is causally important in the improvement in insulin signaling,” they wrote.

As a result, there “appear to be two separate CaMKII pathways,

• one involved in CaMKII-p38-FoxO1 dependent hepatic glucose production, and
• the other involved in defective insulin-induced p-Akt,” they wrote.

The findings suggest the possibility of a drug that can target both hyperglycemia and insulin resistance in type 2 diabetes, they said.

Association Between a Genetic Variant Related to Glutamic Acid Metabolism and Coronary Heart Disease in Individuals With Type 2 Diabetes

Lu Qi; Qibin Qi; S Prudente; C Mendonca; F Andreozzi; et al.
JAMA. 2013;310(8):821-828.     http://dx.doi.org/10.1001/jama.2013.276305.

Importance

Diabetes is associated with an elevated risk of coronary heart disease (CHD). Previous studies have suggested that the genetic factors predisposing to excess cardiovascular risk may be different in diabetic and nondiabetic individuals.

Objective

To identify genetic determinants of CHD that are specific to patients with diabetes.

Design, Setting, and Participants

We studied 5 independent sets of CHD cases and CHD-negative controls from the Nurses’ Health Study (enrolled in 1976 and followed up through 2008), Health Professionals Follow-up Study (enrolled in 1986 and followed up through 2008), Joslin Heart Study (enrolled in 2001-2008), Gargano Heart Study (enrolled in 2001-2008), and Catanzaro Study (enrolled in 2004-2010). Included were a total of 1517 CHD cases and 2671 CHD-negative controls, all with type 2 diabetes. Results in diabetic patients were compared with those in 737 nondiabetic CHD cases and 1637 nondiabetic CHD-negative controls from the Nurses’ Health Study and Health Professionals Follow-up Study cohorts. Exposures included 2 543 016 common genetic variants occurring throughout the genome.

Main Outcomes and Measures

Coronary heart disease—defined as fatal or nonfatal myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, or angiographic evidence of significant stenosis of the coronary arteries.

Results

A variant on chromosome 1q25 (rs10911021) was consistently associated with CHD risk among diabetic participants,

• with risk allele frequencies of 0.733 in cases vs 0.679 in controls (odds ratio, 1.36 [95% CI, 1.22-1.51]; P = 2 × 10−8).

No association between this variant and CHD was detected among nondiabetic participants, with risk allele frequencies of 0.697 in cases vs 0.696 in controls (odds ratio, 0.99 [95% CI, 0.87-1.13]; P = .89),

• consistent with a significant gene × diabetes interaction on CHD risk (P = 2 × 10−4).

Compared with protective allele homozygotes, rs10911021 risk allele

• homozygotes were characterized by a 32% decrease in the expression of the neighboring glutamate-ammonia ligase (GLUL) gene in human endothelial cells (P = .0048).
• A decreased ratio between plasma levels of γ-glutamyl cycle intermediates pyroglutamic and glutamic acid was also shown in risk allele homozygotes (P = .029).

Conclusion and Relevance

A single-nucleotide polymorphism (rs10911021) was identified that was significantly associated with CHD among persons with diabetes but not in those without diabetes and was functionally related to glutamic acid metabolism, suggesting a mechanistic link.

Adipocyte Heme Oxygenase-1 Induction Attenuates Metabolic Syndrome In Both Male And Female Obese Mice

Angela Burgess1,2, Ming Li2, Luca Vanella1, Dong Hyun Kim1, Rita Rezzani4, et al.

1Department of Physiology and Pharmacology, University of Toledo, Toledo, OH 43614
2Department of Pharmacology, New York Medical College, Valhalla, NY 10595
3Department of Medicine, New York Medical College, Valhalla, NY 10595
4Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
5Department of Pediatrics and Center for Applied Genomics, Charles University, Prague, Czech Republic
6The Rockefeller University, New York, New York 10065

Hypertension. 2010 December ; 56(6): 1124–1130.    http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.151423

Abstract

Increases in visceral fat are associated with

• increased inflammation,
• dyslipidemia,
• insulin resistance,
• glucose intolerance and
• vascular dysfunction.

We examined the effect of the potent heme oxygenase (HO)-1 inducer, cobalt protoporphyrin (CoPP), on regulation of adiposity and glucose levels in both female and male obese mice. Both lean and obese mice were administered CoPP intraperitoneally, (3mg/kg/once a week) for 6 weeks. Serum levels of

1. adiponectin,
2. TNFα,
3. IL-1β and
4. IL-6, and
5. HO-1,
6. PPARγ,
7. pAKT, and
8. pMPK protein expression

were measured in adipocytes and vascular tissue . While female obese mice continued to gain weight at a rate similar to controls, induction of HO-1 slowed the rate of weight gain in male obese mice. HO-1 induction led to lowered blood pressure

levels in obese males and females mice similar to that of lean male and female mice.

HO-1 induction also produced a significant decrease in the plasma levels of IL-6, TNF-α, IL-1β and fasting glucose of obese females compared to untreated female obese mice. HO-1 induction

• increased the number and
• decreased the size of adipocytes of obese animals.

HO-1 induction increased adiponectin, pAKT, pAMPK, and PPARγ levels in adipocyte of obese animals. Induction of HO-1, in adipocytes was associated with

• an increase in adiponectin and
• a reduction in inflammatory cytokines.

These findings offer the possibility of treating not only hypertension, but also other detrimental metabolic consequences of obesity

• including insulin resistance and dyslipidemia in obese populations
• by induction of HO-1 in adipocytes.

Introduction

Moderate to severe obesity is associated with increased risk for cardiovascular complications and insulin resistance in humans1, 2 and animals3, 4. Cardiovascular risk is specifically associated with increased intra-abdominal fat. Women in their reproductive years have a higher BMI than males, which largely reflects increased overall subcutaneous adipose tissue or “gynoid” obesity, this is not associated with increased cardiovascular risk5. However, due to increases in visceral fat with aging, after the age of 60 the fat distribution in females more closely resembles that in males6. Increased androgen levels also often occur after the menopausal transition. These changes in visceral fat content and androgen levels correlate with both central obesity and insulin resistance and are an important determinant of cardiovascular risk7.

Heme oxygenase (HO) catalyzes the breakdown of heme, a potentially harmful pro-oxidant, into its products biliverdin and carbon monoxide, with a concomitant release of iron (reviewed in8). While HO-2 is expressed constitutively, HO-1 is inducible in response to oxidative stress and its induction has been reported to normalize vascular and renal function9–11. Further, induction of HO-1 slows weight gain, decreases levels of TNF-α and IL-6 and increases serum levels of adiponectin in obese rats and obese diabetic mice4, 9, 12.

The association observed between HO-1 and adiponectin has led to the proposal of the existence of a cytoprotective HO-1/adiponectin axis4, 13. Previously, L’Abbate et al,14 have shown that induction of HO-1 is associated with a parallel increase in the serum levels of adiponectin, which has well-documented

1. insulin-sensitizing,
2. antiapoptotic,
3. antioxidative and
4. anti-inflammatory properties.

Adiponectin is an abundant protein secreted from adipocytes. Once secreted, it mediates its actions by binding to a set of receptors, such as

• adipoR1 and adipoR2, and also
• through induction of AMPK signaling pathways15, 16.

In addition, increases in adiponectin play a protective role against TNF mediated endothelial activation17.

In this study, we evaluated the effect of CoPP, a potent inducer of HO-1,

• on visceral and subcutaneous fat distribution in both female and male obese mice.

We show for the first time a resistance to weight reduction upon administration of CoPP in female obese mice but

• a significant decrease in inflammatory cytokines.

Despite continued obesity,

1. CoPP normalized blood pressure levels,
2. decreased circulating cytokines, and
3. increased insulin sensitivity in obese females.

CoPP treatment of obese mice

• increased the number and
• reduced the size of adipocytes.

CoPP treatment of both male and female obese mice reversed the reduction in adiponectin levels seen in obesity. This study suggests that in spite of continued obesity,

• HO-1 induction in female obese mice serves a protective role against obesity associated metabolic consequences via expansion of healthy smaller insulin-sensitive adipocytes.

Results

Effect of induction of HO-1 on body weight, appearance, and fat content of female and male obese mice. Previously, we have shown CoPP treatment results in the prevention of weight gain in several male models of obesity including obese and db/db mice and Zucker fat rats4, 12. We extended our studies to examine the effect of CoPP on weight gain in female obese mice. CoPP-treatment prevented weight gain in male obese mice when compared to age-matched male controls (Figure S1). The revention of body weight gain was accompanied by a

reduction in visceral fat in male obese mice. However, female obese mice administered CoPP did not lose weight but continued to gain weight at the same rate as untreated female obese mice (Figure S1). This was in spite of food intake being comparable between the two

groups. CoPP administration decreased subcutaneous fat content in both obese males and females (p<0.05; p<0.05, respectively). CoPP produced a decrease (p<0.05) in visceral fat in male but not in female obese mice when compared to untreated obese mice (Figure S1D).

We examined adipocyte size by haematoxilin-eosin staining in both lean, obese and CoPP treated obese female mice (Figure 1A, upper panel). CoPP treatment resulted in a decrease in adipocyte size (p<0.05) compared to untreated obese animals (Figure 1A, lower left panel). We then examined the number of adipocytes in lean, obese and CoPP-treated obese female mice. The number of adipocytes (mean±SE) in lean, obese and CoPP-treated obese animals was 40.83±3.50, 18.33±1.80 and 32.00±1.67 respectively indicating that CoPP treatment of obese mice increased the number of adipocytes to levels similar to those in lean animals (Figure 1A, lower right panel). Similar results were seen in male animals.

The induction of HO-1 was associated with a reduction in blood pressure (BP). Systolic blood pressure in obese female mice was 142 ± 6.5 mm Hg compared to obese-CoPP treated, 109 ± 8.1 mm Hg, p<0.05. The value in obese female mice treated with CoPP is similar to the blood pressure seen in lean female mice (110 ± 9.6 mm Hg). The systolic blood pressure in obese male mice was 144± 4.5 mm Hg compared to obese-CoPP treated, 104 ± 3.6 mm Hg, p<0.05.

We further examined whether CoPP affects HO-1 expression in adipocyte using immunohistochemistry and western blot analysis. Immunostaining showed increased levels of HO-1 (green staining), located on the surface of adipocytes, after CoPP treatment (p<0.05), compared with female obese mice, Figure 1B. As seen in Figure 1C, HO-1 and

HO-2 levels in adipocyte isolated from lean, untreated female obese mice or female obese mice treated with CoPP. Densitometry analysis showed that HO-1 was increased

significantly in female obese mice treated with CoPP, compared to non-treated female obese mice, p<0.05, which is in agreement with immunohistochemistry results. This pattern of HO expression in obesity occurs in other tissues, including aortas, kidneys and hearts of male obese mice4, 13.

Effect of CoPP on HO-1 expression and HO activity in female and male obese mice

HO-1 protein levels were increased by CoPP treatments in liver and renal tissues similar to that seen in adipocytes. Western blot analysis showed significant differences  (p<0.05) in the ratio of HO-1 to actin in renal of male and female obese and lean mice (Figure S 2A). Obesity decreasd HO-1 levels in both sexes when compared to age matched lean animals.

In addition, HO-1 levels were significantly (p<0.05) lower in obese females compared to obese males (Figure S 2A). This reflects a less active HO system in both male and female

obese animals compared to age matched lean controls. Next, we compared the effect of CoPP on male and female HO-1 gene expression in adipocytes. CoPP increased HO-1

expression in both male and female obese animals compared to untreated obese animals (Figure S 2B, p<0.001 and p<0.001, respectively). Similar results of HO-1 expression were seen in liver tissues (Result not shown).

Effect of CoPP on cytokine levels in female and male obese mice

CoPP administration resulted in a significnt increase in the levels of plasma adiponectin in both female (p<0.001) and male obese (p<0.001) mice (Figure 2A). Untreated female obese animals exhibited a significant (p<0.05) increase in plasma IL-6 levels when compared to age-matched male obese mice (Figure 2B). CoPP decreased plasma IL-6 levels in both female and male obese mice (p<0.05A )p<0.01, respectively) when compared to untreated obese miec. Similar results were observed with plasma TNF-α and IL-1β levels (Figure 2C and 2D). These results indicate that though female obese mice exhibited elevated serum levels of inflammatory cytokines compared to male obese mice, CoPP acts with equal efficacy in both female and male obese animals in reducing inflammation while simultaneously increasing serum adiponectin levels (Figure 2). 

Effect of CoPP on blood glucose and LDL levels in female and male obese mice 

Fasting glucose levels were determined after the development of insulin resistance. CoPP produced a decrease in glucose levels in both fasting female (p<0.05) and male (p<0.001) obese mice when compared to untreated obese control animals (Figure 3A). CoPP reduced LDL levels in both male (p<0.01) and female (p<0.05) obese mice when compared to untreated obese controls (Figure 3B). Treatment with SnMP, increased LDL levels. In separate experiments two weeks apart, glucose levels and insulin sensitivity were determined after development of insulin resistance (Fig. 4A and B). Blood glucose levels in female obese mice were elevated (p<0.01) 30 min after glucose administration and remained elevated. In CoPP-treated female obese mice produced a decrease in glucose but not in the vehicle-treated female obese mice (p<0.01).

Effect of Obesity on Protein Expression Levels of pAKT, pAMPK, and PPARγ levels in female and male obese mice

Western blot analysis of adipocytes harvested from fat tissues,showed significant  differences in basal protein expression levels of pAKT and pAMPK in untreated female obese mice compared to untreated obese male mice. pAMPK levels were higher in obese females compared to obese males (Figure 5A, p< 0.05). This was also the case for pAKT protein levels, where increased levels of pAKT were seen in obese females compared to obese males (Figure 5B, p<0.05). CoPP treatment increased pAMPK and pAKT levels in bothe obese females and obese males. In addition, CoPP administration increased PPARγ levels, in both male (p<0.001) and female (p<0.05) obese mice (Figures 5C).

Discussion

In the current study, we show for the first time that induction of HO-1 regulates adiposity in both male and female animals via an increase in adipocyte HO-1 protein levels. A second novel finding is that induction of HO-1 was associated not only with a decrease in adipocyte cell size but with an increase in adipocyte cell number. Further, induction of HO-1 affects visceral and subcutaneous fat distribution and metabolic function in male obese mice differently than in female obese mice. Despite continued obesity, upregulation of HO-1 induced major improvements in the metabolic profile of female obese mice exhibiting symptoms of Type 2 diabetes including: high plasma levels of proinflammatory cytokines, hyperglycemia, dyslipidemia, and low adiponectin levels. CoPP treatment resulted in increased serum adiponectin levels and decreased blood pressure. Adiponectin is exclusively secreted from adipose tissue, and its expression is higher in subcutaneous rather than invisceral adipose tissue. Increased adiponectin levels reduce adipocyte size and increase adipocyte number12, resulting in smaller, more insulin sensitive adipocytes. Adiponectin has recently attracted much attention because it has insulin-sensitizing properties that enhance fatty acid oxidation, liver insulin action, and glucose uptake and positively affect serum trglyceride levels18–21. Levels of circulating adiponectin are inversely correlated with plasma levels of oxidized LDL in patients with Type 2 diabetes and coronary artery disease, which suggests that low adiponectin levels are associated with an increased oxidative state in the arterial wall22. Thus, increases in adiponectin mediated by upregulation of HO-1 may account for improved insulin sensitivity and reduced levels of LDL and inflammatory cytokines (TNF-α, IL-1β, and IL-6 levels) in both male and female mice.

 Females continued to gain weight in spite of the metabolic improvements. One plausible explanation for this anomaly is the direct effects of HO-1 on adiponectin mediating clonal expansion of pre-adipocytes. This supports the concept that expansion of adipogenesis leads to an increased number of adipocytes of smaller cell size; smaller adipocytes are considered to be healthy, insulin sensitive adipocyte cells that are capable of producing adiponectin23. This hypothesis is supported by the increase in the number of smaller adipocytes seen in

CoPP-treated female obese animals without affecting weight gain when compared to female obese animals. Similar results for the presence were seen in males indicating that this effect is not sex specific.

Upregulation of HO-1 was also associated with increased levels of adipocyte pAKT, and pAMPK and PPARγ levels. Previous studies have indicated that insulin resistance and  impaired PI3K/pAKT signaling can lead to the of endothelial dysfunction24. In the current study, increased HO-1 expression was associated with increases in both AKT and AMPK phosphorylation; these actions may protect renal arterioles from insulin mediated endothelial damage. By this mechanism, increased levels of HO-1 limit oxidative stress and facilitate activation of an adiponectin-pAMPK-pAKT pathway and increased insulin sensitivity. Induction of adiponectin and activation of the pAMPK-AKT pathway has been shown to provide vascular protection25, 26. A reduction in AMPK and AKT levels may also explain why inhibition of HO activity in CoPP-treated obese mice  increased inflammatory cytokine levels while decreasing adiponectin. The action of CoPP in increasing pAKT, pAMPK and PPARγ is associated with improved glucose tolerance and decreased insulin resistant.

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on LinkedIn (Opens in new window)
• Click to share on Facebook (Opens in new window)
• Click to print (Opens in new window)
• Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

Read Full Post »

How Might Sleep Apnea Lead to Serious Health Concerns like Cardiac and Cancers?

Posted in Cancer Prevention: Research & Programs, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Health Economics and Outcomes Research, Medical and Population Genetics, Nutrition, Origins of Cardiovascular Disease, Population Health Management, Nutrition and Phytochemistry, Systemic Inflammatory Response Related Disorders, tagged ApneaSleep, BMI, Body mass index, Cancer - General, CPAP, Diabetes mellitus type 2, metabolic syndrome, Obstructive sleep apnea, OSA, Pasteur effect, physical activity, Positive airway pressure, Sleep apnea, Sleep disorder, subjective global assessment, type 2 DM on March 20, 2013| 2 Comments »

How Might Sleep Apnea Lead to Serious Health Concerns like Cardiac and Cancer?

Author: Larry H Bernstein, MD, FCAP

3.3.16   How Might Sleep Apnea Lead to Serious Health Concerns like Cardiac and Cancer?, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

UPDATED on 7/23/2019

Israel-led research team develops AI-based model to detect sleep apnea | The Times of Israel

https://www.timesofisrael.com/israel-led-research-team-develops-ai-based-model-to-detect-sleep-apnea/?utm_source=dlvr.it

What is the link between sleep apnea and cardiovascular disease and is the treatment of obstructive sleep apnea (OSA) by continuous positive airway pressure in patients (CPAP) with heart failure to improve left ventricular systolic function sufficient?  There are statistics incicating the benefit of CPAP and improvement of LVSF in those patients on CPAP with CHF.  But that observation does not get at why the patients benefit, or whether the OSA is sufficient.  Don’t expect a randomized clinical trial of any design to be brought to bear on the subject, considering the ethical issues involved.  We’ll return to that in a moment.

In a recent study researchers in Spain followed thousands of patients at sleep clinics and found that those with the most severe forms of sleep apnea had a 65 percent greater risk of developing cancer of any kind. The second study, of about 1,500 government workers in Wisconsin, showed that those with the most disordered sleep had five times the rate of dying from cancer as people without the sleep disorder (apnea not specified). Both research teams only looked at cancer diagnoses and outcomes in general.  If I lump the two studies, assuming that all patients with the most disordered sleep had OSA and were on CPAP, what does this tell us?  The heart and lung function together as a cardiopulmonary oxygenation unit!  A problem disrupting oxygenation, such as autonomically controlled sleep disruption or, oronasal obstruction (ASSOCIATED WITH SNORING), would be expected to have an effect on alertness during the day, predisposition to CHF from strain on the CP circulation as well as ventilatory impairment and peripheral oxygenation.  It appears that an association with ANY cancer, unspecified, is a long reach.

In both studies the researchers ruled out the possibility that the usual risk factors for cancer, like

1. age
2. smoking
3. alcohol use
4. physical activity
5. weight

The association between cancer and disordered breathing at night remained

• even after they adjusted for confounding variables.

This led to the conclusion that cancer might be linked to (intermittent) lack of oxygen supply interrupting aerobic cell activity over long periods of time.  The conclusion is drawn that from two associations

• the research on positive outcome from CPAP in OSA and
• a possible link between breathing and cardiac and cancer clearly

demonstrates the importance of regular breathing exercises (other wise known as ‘Pranayama’ in India) as part of our every day life.

This answers the first observation I posed. That is, the use of CPAP, while enormously important, is not sufficient.  Regular breathing exercises would seem to be helpful, although not a standard part of current treatment. This would be especially important if the movement of the abdominal muscles and diaphragm were synchronized with the expansion of the nthorax for maximum air flow.  This observation is familiar from working with a certified exercise physiologist.   The other part of this is an optimum time for walking and carrying out basic muscle and flexibility exercises several times a week, which has been shown repeatedly by studies on health benefits.

It is not my place to raise some questions about the way the studies were carried out.  The patients who have sleep apnea would be expected to have an increased body mass index (BMI), and while not sarcopenic, more likely to have excess body fat, abdominal distribution in males, and hip distribution in females, amd more importantly, unseen fat in the abdominal peritoneum.  This is related to type 2 diabetes with a metabolic syndrome, a separate indicator of CVD risk.   The metabolic syndrome involves TNF-alpha (once also known as cachexin), IL-1, IL-6, C-reactive protein, and in the case of fat signaling, adipokines, as well as insulin resistance and, as a result, some counter-regulatory secretion of glucocorticosteroids.  This metabolic picture would result in the following:

1. impaired glucose utilization
2. some excess and uncompensated gluconeogenesis
3. the impaired lactate reentry at the end of glycolysis
4. an effect on allosteric PFK

Features 1-4 look like what Warburg called a Pasteur Effect, not at the clellular level, but in the whole individual.   While obesity and type 2 diabetes are occuring in the young and adolescent population, the consequences might not be seen until years later.  The consequences could be in a middle aged person falling asleep at a meeting, or a series of automabile accidents related to falling asleep at the wheel.

At a time that clinical laboratory measurements are so accurate, and

• the associations between type 2 diabetes,
• measurement of wt/ht^2,
• arm strength,
• skin fold thickness,

are common measures of fitness, they don’t appear to have any place in these studies. If that is the case, then how is it possible to make sense of a relationship between SEVERITY of sleep disturbance and health outcome.

http://www.nejm.org/doi/full/10.1056/NEJMoa022479#t=articleTop

http://well.blogs.nytimes.com/2012/05/20/sleep-apnea-tied-to-increased-cancer-risk/

http://www.medicalnewstoday.com/articles/245649.php

http://www.sciencenews.org/view/generic/id/340838/title/Severe_s

Related articles

• Sleep Apnea (topdentists.com)
• What Are Sleep Apnea Causes? (topdentists.com)
• Sleep disorder increases risk of brain cancer: Taiwan doctor (wantchinatimes.com)
• Think Sleep Apnea is Just Snoring and Sleepiness? Think Again (sleephelpdesk.wordpress.com)

English: The Cycle of Obstructive Sleep Apnea – OSA (Photo credit: Wikipedia)

English: The graph shows the correlation between body mass index (BMI) and percent body fat (%BF) for men in NCHS’ NHANES III 1994 data. The body fat percent shown uses the method from Romero-Corral et al. to convert NHANES BIA to %BF (June 2008). “Accuracy of body mass index in diagnosing obesity in the adult general population”. International Journal of Obesity 32 (6) : 959–956. DOI:10.1038/ijo.2008.11. PMID 18283284. (Photo credit: Wikipedia)

English: Body mass index, BMI, body size, body weight, mortality Italiano: indice di massa corporea, IMC, altezza corporea, peso corporeo, mortalità (Photo credit: Wikipedia)

Italiano: biometria, epidemiologia, rischio, peso corporeo umano, mortalità, indice di massa corporea, IMC, body mass index, BMI, prospective studies collaboration (Photo credit: Wikipedia)

00

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on LinkedIn (Opens in new window)
• Click to share on Facebook (Opens in new window)
• Click to print (Opens in new window)
• Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

Read Full Post »

BARI 2D Trial Outcomes

Posted in Chemical Biology and its relations to Metabolic Disease, Computational Biology/Systems and Bioinformatics, Health Economics and Outcomes Research, Health Law & Patient Safety, International Global Work in Pharmaceutical, Metabolomics, Molecular Genetics & Pharmaceutical, Nutrigenomics, Nutrition, Origins of Cardiovascular Disease, Pharmaceutical Industry Competitive Intelligence, tagged Angioplasty, Cardiovascular disease, Coronary artery bypass surgery, Coronary artery disease, Diabetes Mellitus, Diabetes mellitus type 2, health, Percutaneous coronary intervention on March 5, 2013| Leave a Comment »

BARI 2D Trial Outcomes

Reporter: Larry H Bernstein, MD, FCAP

Results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial

GR. Dagenais, MD; Jiang Lu, MS; David P. Faxon, MD; Peter Bogaty, MD, et. Al.

 J Am Coll Cardiol. 2013;61(7):702-711. http://dx.doi.org/10.1016/j.jacc.2012.11.036

http://JACC.org/Results_from_the_BARI_2D_(Bypass_Angioplasty_Revascularization_Investigation_2-Diabetes)_Trial

Prognostic Impact of the Presence and Absence of Angina on Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Stable Coronary Artery Disease : 

 

Results from the BARI 2D Trial…Bypass Angioplasty Revascularization Investigation 2 Diabetes

Objectives

The purpose of this analysis was

1. to assess in patients with type 2 diabetes and stable coronary artery disease (CAD)
2. whether the risk of all-cause mortality and cardiovascular events
3. varied according to the presence or absence of angina and angina equivalent symptoms.

Background  Data on the prognostic value of symptoms in these patients are limited.

Methods

Post-hoc analysis was performed in 2,364 patients with type 2 diabetes and documented CAD enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial to determine

1. the occurrence of death and composite of death,
2. myocardial infarction, and
3. stroke

during a 5-year follow-up according to cardiac symptoms at baseline.

Results

There were 1,434 patients with angina (A), 506 with angina equivalents (E), and 424 with neither of these (N).
The cumulative death rates (total 316) were

• 12% in A,
• 14% in E, and
• 10% in N (p = 0.3), and

cardiovascular composite rates (total 548) were

• 24% in A,
• 24% in E, and
• 21% in N (p = 0.5).

Compared with N, the hazard ratios adjusted for confounders were not different for death in

• A (1.11; 99% CI: 0.81 to 1.53) and
• E (1.17; 99% CI: 0.81 to 1.68) or

for cardiovascular events in

• A (1.17; 99% CI: 0.92 to 1.50) and
• E (1.11; 99% CI: 0.84 to 1.48).

Conclusions

Whatever their symptom status,

• patients with type 2 diabetes and stable CAD were at similar risk of cardiovascular events and death.

These findings suggest that these patients

• may be similarly managed in terms of risk stratification and preventive therapies.

(Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D]; NCT00006305)

Key Words

• angina;
• coronary artery disease;
• silent ischemia;
• type 2 diabetes

Abbreviations and Acronyms

• BMI, body mass index;
• CABG, coronary artery bypass graft surgery;
• CAD, coronary artery disease;
• CVD,cardiovascular disease;
• HbA_1c, glycosylated hemoglobin;
• MI, myocardial infarction;
• PCI, percutaneous coronary intervention

Prognostic Impact of the Presence and Absence of Angina on Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Stable Coronary Artery Disease
http://www.ncbi.nlm.nih.gov/pubmed/23410541

J Am Coll Cardiol. 2013 Feb 19;61(7):702-11.   http://dx. doi.org/ 10.1016/j.jacc.2012.11.036.

http://www.j.JACC.org/Prognostic Impact of the Presence and Absence of Angina on Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Stable Coronary Artery Disease

Prognostic Impact of the Presence and Absence of Angina on Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Stable Coronary Artery Disease: Results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group.        PMID: 23410541 [PubMed – in process]
Source: Quebec Heart and Lung University Institute, Quebec City, Quebec, Canada. Electronic address: gilles.dagenais@criucpq.ulaval.ca.

Diabetes Mellitus (Photo credit: anaxolotl)

Micrograph of an artery that supplies the heart with significant atherosclerosis and marked luminal narrowing. Tissue has been stained using Masson’s trichrome. (Photo credit: Wikipedia)

Bildbeschreibung: Deutsch: Koronarangiografie und PTCA bei akutem Hinterwandinfarkt (li.: RCA verschlossen, re.: RCA erfolgreich dilatiert) Quelle: Deutsch: Scan von 2 Videoprints einer selbst durchgeführten Prozedur Fotograf/Zeichner: selbst gescannt / own work Datum: ca. 1999 (hochgeladen 03. Oktober 2005) andere Versionen: (Photo credit: Wikipedia)

Related articles

• Pharma Intell Posts
  http://pharmaceuticalintelligence.com/2012/08/29/positioning-a-therapeutic-concept-for-endogenous-augmentation-of-cepcs-therapeutic-indications-for-macrovascular-disease-coronary-cerebrovascular-and-peripheral/
  http://pharmaceuticalintelligence.com/2012/08/28/cardiovascular-outcomes-function-of-circulating-endothelial-progenitor-cells-cepcs-exploring-pharmaco-therapy-targeted-at-endogenous-augmentation-of-cepcs/
  http://pharmaceuticalintelligence.com/2012/08/27/endothelial-dysfunction-diminished-availability-of-cepcs-increasing-cvd-risk-for-macrovascular-disease-therapeutic-potential-of-cepcs/
  http://pharmaceuticalintelligence.com/2012/07/02/macrovascular-disease-therapeutic-potential-of-cepcs-reduction-methods-for-cv-risk/
  http://pharmaceuticalintelligence.com/2012/11/05/cabg-or-pci-patients-with-diabetes-cabg-rein-supreme/
  http://pharmaceuticalintelligence.com/2012/08/20/therapeutic-targets-for-diabetes-and-related-metabolic-disorders/
• RSNA – CT Angiography Helps Predict Heart Attack Risk (prweb.com)
• Men Experiencing Permanent Stress At Increased Risk For Type 2 Diabetes (medicalnewstoday.com)
• Type 2 Diabetes Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Age 18+ with Type 2 Diabetes (prweb.com)
• Determining Heart Attack Risk In Suspected Coronary Artery Disease (medicalnewstoday.com)
• CABG leads to fewer MIs and repeat revascularization vs. stenting (2minutemedicine.com)
• CT angiography helps predict heart attack risk (eurekalert.org)
• New hope in fight against diabetes (express.co.uk)

00

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on LinkedIn (Opens in new window)
• Click to share on Facebook (Opens in new window)
• Click to print (Opens in new window)
• Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

Read Full Post »

Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Email Address

  Follow

  Join 9,459 other subscribers

• Recent Posts

  • Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
  • The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
  • Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
  • Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
  • Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
  • Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
  • Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
  • Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
  • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
  • Verily announced other organizational changes, 1/13/2023 January 16, 2023

• Archives

  Archives Select Month March 2023  (5) February 2023  (2) January 2023  (3) December 2022  (2) October 2022  (6) September 2022  (2) August 2022  (1) July 2022  (3) June 2022  (3) May 2022  (8) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (231)    3D Plotting Scaffolds  (43)    BioInks  (33)       Biopolymer Blend Open Porous  (17)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (73)       Cell Level  (13)       MicroEngineering Cell-Tissue & Systems  (30)       Tissue Engineering  (35)    Cardiovascular and Vascular Systems  (27)       Artificial Vascular Structures  (9)       Cardiovascular Tissue  (8)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (8)    MEMS  (16)       Bio-MEMS  (12)    Organ-on-a-Chip  (11)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (9) Academic Publishing  (222)    Key Opinion Leaders in eScientific Publishing – Interviews with  (8) Advanced Drug Manufacturing Technology  (92)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (11)    Automated Cell Processing  (12) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (158)    Etiology  (76)    Medical Device Therapies for Altzheimer’s Disease  (14)    Pharmacotherapy and Cell Activity  (48) Anticancer Resistance  (28) Art Exhibits on the Human Condition  (1) Art Inspires Science  (3) Artificial Heart  (2) Artificial Intelligence – General  (182)    An executive’s guide to AI  (9)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (91)    Artificial Intelligence Applications in Health Care  (90)       Artificial Intelligence in CANCER  (25)       Artificial Intelligence in Health Care – Tools & Innovations  (52)    Artificial Intelligence in Medicine – Application for Diagnosis  (50)       Artificial intelligence applications for cardiology  (22)          AI-assisted Cardiac MRI  (9)       Artificial Intelligence in Psychiatry  (5)       Deep Learning in Pathology  (13)    Artificial Intelligence in Medicine – Applications in Therapeutics  (44)    Machine Learning  (39)       Deep Learning  (5)       Natural Language Processing (NLP)  (20)    Machine learning in predicting type 2 diabetes  (1) Auditory and vision  (13) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (19)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (2)    Ulcerative Colitis  (3) Autophagosome  (2) Bacterial Resistance  (25) Behavior  (26) Behavioral Genetics  (21) Big Data  (75)    Intelligent Information Systems  (46) Bio Instrumentation in Experimental Life Sciences Research  (364)    Analytical Instruments Industry  (5)    Microfuidics  (7) Bio-Ethics  (14) BioBanking  (33) Biodegradable Drug-eluting Material  (7) Bioengineering & reverse engineering design  (41) BioIT: BioInformatics  (142) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (123)    Advanced Computing Platform  (30)       Blockchain Transactions System  (6)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (3)    Simulation Modeling in NGS  (3) Biological Engineering  (39) Biological Networks  (189) Biological Networks, Gene Regulation and Evolution  (472)    Virology  (10) Biomarkers & Medical Diagnostics  (564)    VOC – Volatile Organic Compounds as BioMarkers  (2) Biomedical Measurement Science  (171) BioSimilars  (111) BioTechnology – Venture Creation  (125)    Foundations for supporting Science and Education  (12)    Philanthropy to Academic Institution  (2) BioTechnology – Venture Creation, Venture Capital  (105)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (82) Brain Basis of Emotion  (5) Business Career Consideration  (1) Ca2+ triggered activation  (59) Calcium  (19) Calcium Signaling  (67) Calmodulin Kinase and Contraction  (34) Cancer – General  (175) Cancer and Current Therapeutics  (395)    interventional oncology  (42)       Breast Cancer – impalpable breast lesions  (17)       Prostate Cancer: Monitoring vs Treatment  (8) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,090)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (69)       Circulating Tumor Cells (CTC)  (19)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (14)             mRNA  (5)          MagSifter chip  (1)       KRAS Mutation  (6)       Li-fraumeni syndrome.  (3)       TP53 – Germline mutations  (5)    cancer metabolism  (20)    Funding Opportunities for Cancer Research  (11)    Genomic Expression  (143)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (18)    Metabolic Immuno-Oncology  (15)    Metastasis Process  (12)    Methylation  (31)    Microbiome and Responses to Cancer Therapy  (5)    Monoclonal Immunotherapy  (27)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (9)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (13)    Warburg effect  (50) Cancer Informatics  (93) Cancer Prevention: Research & Programs  (125) Cancer Screening  (102) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (25)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (1) Cardiac and Cardiovascular Surgical Procedures  (318)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (86)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (1)       TAVI vs Open Heart Surgery  (5)       Transcatheter Aortic Valve Replacement via the Transcarotid Access  (1)       Transcaval TAVR Procedure  (2)       Valve-in-Valve Procedure  (3)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (17)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (46)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (14)    Heart-Lung Transplant  (9)    Implantation  (2)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (18)    Mitral Valve: Repair and Replacement  (63)       TMVR – Transcatheter Mitral Valve Repair  (4)    PCI  (104)       Bioresorbable Vascular Scaffold (BVS)  (3)       Invasive FFR for PCI  (2)       Multivessel PCI FFR Guidance  (1)       Robotic-assisted percutaneous coronary intervention  (1)       Stent Retriever in endovascular thrombectomy  (2)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (62)       Abdominal Aorta  (19)       Carotid Artery  (15)       Limb ischemia  (4)       Thoracic Aorta  (15)    Pulmonary Valve Replacement and Repair  (2)    Renal Denervation  (20)    Replacement  (1)    Robotically assisted Cardiothoracic Surgery  (1)    Tricuspid Valve Repair  (6)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (1) Cardiovascular Pharmacogenomics  (168) Cargo  (3) Cell Biology  (318) Cell Biology, Signaling & Cell Circuits  (661)    Apoptosis  (16)    Autophagy-Modulating Proteins  (5)    “Antibody–enzyme conjugates”  (4)    Cell Processing System in Cell Therapy Process Development  (24)    Endoplasmic reticulum  (2)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (3)    Ubiquitin  (9) Cerebrovascular and Neurodegenerative Diseases  (122)    Stroke  (8) Chemical Biology and its relations to Metabolic Disease  (460)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (7) Chemical Genetics  (349) Child and Adolescent Psychiatry  (13) Childhood cancer  (14) Childhood malnutrition  (3) children  (1) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (234) Clinical Diagnostics  (215)    Mass automation of plasma proteins  (13) Clinical Genomics  (135) Coagulation Therapy and Internal Bleeding  (83) Cognition  (46) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (464)    Computational Histopathology  (2)    Meta-analysis of transcriptome data  (8) Conference Coverage with Social Media  (475)    MassBio  (3) coronavirus  (18) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (188)    CRISPR alternative for editing genes without cutting  (14)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (10)       Gene Editing Impact on Longevity  (4) CT  (19) Cytokines  (19) Cytoskeleton  (84) Developmental biology  (105) Diabetes Mellitus  (141)    Artificial Pancreas for Type 2 Diabetes  (1)    Artificial Pancreas for Type1 Diabetes  (5)    Gestational diabetes  (2) Diagnostic Immunology  (56) Diagnostics and Lab Tests  (126)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (8) Digital HealthCare – biotech & internet joint ventures  (46) Disease Biology  (331) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (483) DNA repair  (71)    Apoptosis  (11)    Autophagy  (12)    Cell death pathways  (18)    Proteolysis  (8)    Proteosome  (8) Drug Delivery Platform Technology  (154)    Drug Carrier Design  (19)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (9) Embryology  (24) Empathy  (6) Endocrine Diseases  (59) Enzyme Induction  (45)    ion-transporting enzyme  (1)    K + -ATPase.  (1)    Na +  (2) Epigenetics and Environmental Factors  (31) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (68) FDA Regulatory Affairs  (355)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (52)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (5) Frontiers in Cardiology and Cardiovascular Disorders  (916)    Acute Myocardial Infarction  (60)       Cardiogenic Shock  (4)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (57)    Cardiovascular Research  (183)       Myocardial metabolism, Myocardial ischemia, myocardial perfusion, Myocardial adenine nucleotide metabolism  (62)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (19)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (107)       Ablation Procedure vs Drug Therapy  (2)       Arrhythmia Detection with Machine Learning Algorithms  (6)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (2)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (5)    Epigenetics and Cardiovascular Risks  (55)    Heart Failure (HF)  (46)       Acute coronary syndrome  (6)       congestive heart failure  (17)    Medical Devices R&D and Inventions  (207)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (89)       Valves & Tools  (64)    Origins of Cardiovascular Disease  (416)       Atherogenic Processes & Pathology  (177)       Congenital Heart Disease  (34)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (11)       Systemic Inflammatory Diseases as CVD Risk  (10)    Pharmacotherapy of Cardiovascular Disease  (352)       HTN  (172)       HTN in Youth  (7)       Resident-cell-based  (43)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (13)       endovascular thrombectomy  (5)    Vascular Diseases  (20)       mesenteric ischemia  (3) Future Pandemics Inform-graphics  (1) Gastroenterology  (37) Gene Regulation  (226) Gene Regulation and Evolution  (134) Genetics & Innovations in Treatment  (170) Genetics & Pharmaceutical  (199) Genome Biology  (956)    Exosomes  (24)    Gene Therapy & Gene Editing Development  (37)    mRNA Therapeutics  (17)    Mutagenesis  (26)    Single Cell Genomics  (22)    Single-cell sequencing  (18)    Variation in human protein-coding regions  (30) Genomic Endocrinology  (41) Genomic Testing: Methodology for Diagnosis  (412) Genomics Pharmacy  (37) Global Market of Medical Devices Technology  (2) Global Medical Publishers by Country  (3) Global Partnering & Biotech Investment  (45) GLP  (4) Glycobiology: Biopharmaceutical Production  (14) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (26) Health Care System by Country  (45)    AI Models in Healthcare  (6)    Centers for Medicare & Medicaid Services  (7)    Health in Israel  (2)    United States  (21)       Hospital-based Medical Innovations  (7)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (376)    Women Health  (13)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (160)    and Bioethics  (13)    Biotechnology  (11)    Health Law Policy  (10) HealthCare IT  (136) Healthcare Reform  (109)    Accountable Care Organizations  (25)    Affordable Care Act  (29)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (25)    Healthcare costs and reimbursement  (54)    Indigent Nutrition  (13)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (21)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (19) Hematology  (99)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (235) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (20) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (125)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (126)    Cancer-Immune Interactions  (20)    CNS-Immune Interface  (3)    Neuronal Circuits  (4) Immunology  (112)    Adaptive Immune Response to Biomaterials and Tissue Repair  (9)    Antibody Responses Predict Antigen Exposure  (15)    Cytokine Receptor Structure  (7)    Human Antibody Response  (15)    Human Circulating Antibody Repertoire  (9)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (7)    Synthetic Immunology: Hacking Immune Cells  (12) Immunotherapy  (119)    CAR-T  (13)    combination immunotherapies.  (11)    Efficacy of Anti-Tumor T Cells  (11)    Engineering Better T Cells  (7)    Immune Engineering  (13)    Immune Modulatory  (13)    Integrin-targeted Combination Immunotherapy  (5)    Modulating Macrophages in Cancer Immunotherapy  (11)    NK Cell-Based Cancer Immunotherapy  (16)    Synergistic Innate and Adaptive Immunotherapy  (13) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (161)    Antibiotic resistance  (6)    Viral diseases  (37)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (56)    Virology – Vector-borne DIsease  (17) Inflammasome  (26)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (2) Innovation in Immunology Diagnostics  (105)    Universal Immune Cell Therapies (uICT)  (9) Innovations  (185)    R&D Expenditure  (8) Innovations in Neurophysiology & Neuropsychology  (142)    Age and Life Expectancy  (1)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (2)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (75)    Disputes and Settlements  (8)    IP Valuation Models – Pricing Intangible Assets  (5)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (106) International Global Work in Pharmaceutical  (188) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (297)    Albany Medical Center Prize in Medicine and Biomedical Research  (1)    Annual Breakthrough Prize  (2)    Annual Lewis S. Rosenstiel Award  (1)    Awards in Cardiology and Cardiovascular Medicine  (3)    CEOs of Biotech Companies  (2)    Gerald D Aurbach Award for Outstanding Translational Research  (1)    Interviews with Key Opinion Leaders (KOLs)  (6)    James Prize in Science and Technology Integration  (1)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (1)    Lemelson-MIT Prize  (1)    Life Sciences Breakthrough Prize  (2)    Mosteller Statistician of the Year Award  (1)    Mourning the Loss of a Scientific Leader  (2)    National Academy of Sciences AWARDS  (2)    Nobel Prize WInners  (20)    Noble Prize (Not Nobel Prize)  (1)    Paul Marks Prize for Cancer Research  (1)    Russ Prize recognizes bioengineering achievements worldwide  (1)    The Dan David Prize  (5)    Warren Alpert Foundation Prize Recipients  (3)    Wolf Prize  (1)    Wolf Prize in Medicine  (1)    women in science  (3) Investment in Technological Breakthrough  (59) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (9) IP Development by LPBI Group Team & Other Organizations  (7) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (13) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (108)    Fatty acids  (37)    Lipids  (37)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (10) Liposome  (3) Liver & Digestive Diseases Research  (119) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (128)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (7)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (21)    PhD  (1)    RN  (1) LPBI Management  (15) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (36)    Organic BioElectronics  (1) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (190) Medical Devices R&D Investment  (239)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (13)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (55) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (160)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (3)    Echocardiography  (2)    MRI  (17)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (5)    Ultra Sound  (7) Melatonin & Circadian Regulation  (9) memory loss  (1) Metabolism  (235)    Biochemical pathways  (141)       Enzymes and isoenzymes  (71)          Dehydrogenase  (15)          Kinase  (27)          Phosphatase  (8)          Phosphorylase  (21)          tyrosine decarboxylases  (2)    Inosine nucleotides  (8)    Leloir pathway  (6)    microbiome  (6)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (317) Methods  (37) Mg++  (10) Microbiologial genetics  (33) Microbiology  (67)    Virology  (14) Micronutrients  (15) Microvesicle  (6) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (4) Molecular Genetics & Pharmaceutical  (374)    Organoids  (3) Monoclonal antibody therapy  (13) Mutant Gene Expression  (41) Myocardial adenine nucleotide metabolism  (5) Myocardial Ischemia  (25) Myocardial Metabolism  (35) Na-K transport  (39) Na-K-ATPase  (26) Nanotechnology for Drug Delivery  (96) Nephrology  (46) Nephrology & Regenerative medicine  (9) Neurodegenerative Diseases  (86)    hNPCs  (3)    MS  (5) Neurohumoral Transmission  (66)    Ca2+ triggered activation  (19)    Calmodulin  (12)    Parkinson’s disease dyskinesia levodopa  (3)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (120) Neuroscience  (126) Next Generation Sequencing (NGS)  (24)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (135) Nuclear Medicine  (11) Nutrigenomics  (67) Nutrition  (193)    Nutritional Supplements: Atherogenesis, lipid metabolism  (48) Nutrition and Phytochemistry  (60)    Minerals in Medicine  (4)    Plant extract  (22) Nutrition Disorders  (29) Nutritional Supplements: Atherogenesis  (30) Obesity  (17) Oligonucleotide Therapeutics & Delivery  (6) Oncolytic virus & OncoViro-Therapy  (21)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (24) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (34) Patient Experience  (64)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (7) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (1) Personal Health Applications: Tech Innovations serves HealhCare  (35) Personalized and Precision Medicine & Genomic Research  (715)    Longevity  (1)    New Drug Approval  (4)    Patient-centered Medicine  (34)       cell-based therapy  (8)       stem cell biology and patient-specific  (6)    Personalized Medicine Coalition  (8)    Precision Cancer Medicine  (17) Phagophore  (1) Pharmaceutical Analytics  (258)    Pharmacologic toxicities  (61) Pharmaceutical Discovery  (106)    Rapid automation of plasma protein pools  (16) Pharmaceutical Drug Discovery  (194)    Drug Development Process  (51)       Drug Discovery Chemistry  (27)    drug repurposing  (8) Pharmaceutical Industry Competitive Intelligence  (338)    Pharmacovigilance  (6)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (42) Pharmaceutical R&D Investment  (297) Pharmacodynamics and Pharmacokinetics  (23) Pharmacogenomics  (156) Photography Collection  (1) Physics  (12) Placenta  (7) Population genetics  (25) Population Health Management  (189)    Evolution of Biology Through Culture  (13)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (620)    COVID-19  (155)       Biomarkers: Inflammation  (36)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (138)       Coronavirus Gene Expression  (65)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (18)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (29)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (35)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (150) Preimplantation Genetic Diagnosis and Reproductive Genomics  (12) Protein-energy malnutrition  (11) Proteomics  (359)    Amino acids  (51)    Proteins  (133) Pulmonary diseases  (16)    Lung and pulmonology  (15) Pulmonary pathology  (8) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (30) Regenerative Biology and Medicine  (91) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (111) Reproductive Biology & Bio Instrumentation  (76) RNA Biology  (79)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (61) RVAD  (1) SBIR, SBA, NIH, NSF  (3) Schizophrenia  (16) Scientific & Biotech Conferences: Press Coverage  (172) Scientific Publishing  (606)    Curation  (583)       Curation methodology  (40)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (71)       Evolutionary cognition  (52)       Experimental validation  (90)       Explanatory  (91)       Historical relevance  (71)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (36) Scientist: Career considerations  (193)    Big Data & Analytics  (14)    Data Science  (10)    Women in Life Sciences  (11) Scoop.it  (19) Sensors & Analytics  (17) Sepsis  (2) Severe Autism  (3) Signaling  (99)    Phosphorylation  (41)    S-nitrosylation  (12)    Ubiquitinylation  (32) Signaling & Cell Circuits  (128) single cell sequencing  (1) Small Molecules in Development of Therapeutic Drugs  (69) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (136) Stem Cells for Regenerative Medicine  (174)    Cardiac muscle regeneration  (18)    Competition in regenerative stem cell science  (17)    Human neural progenitor cells  (7)    Skeletal muscle regeneration  (8) STORM  (2) Stress Disorders  (18) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (158)    Inflammatory Pathophysiology  (6) Technology Transfer: Biotech and Pharmaceutical  (351) therapeutics  (2) Tissue Engineering and Regenerative Medicine  (21) Tissue Microenvironment  (3) Transarterial Chemoembolization  (2) Transcriptomics  (42) Transformative Technologies in Healthcare  (12) Translational Science  (223)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (26)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (6)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (88) Trends in Global Economy  (6) Uncategorized  (1,007) Unfolded Protein Response (UPR)  (5) US and Global Economy: Trends and Findings  (8) Venture Capital  (44)    Income Geographic Distribution  (2)    Institutional Capital Raised by Female Founders  (5) virology  (9) Vision  (6) Voices of Patients and Healthcare Providers  (21) Water Transporters  (7) Wearable Tech + Digital Health  (3) Anemia  (21) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (12) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • Amandeep Kaur
  • Aashir Awan, Phd
  • Abhisar Anand
  • Adina Hazan
  • Alan F. Kaul, PharmD., MS, MBA, FCCP
  • alexcrystal6
  • anamikasarkar
  • apreconasia
  • aviralvatsa
  • David Orchard-Webb, PhD
  • danutdaagmailcom
  • Demet Sag, Ph.D., CRA, GCP
  • Dror Nir
  • dsmolyar
  • Ethan Coomber
  • evelinacohn
  • Gail S Thornton
  • Irina Robu
  • jayzmit48
  • jdpmd
  • jshertok
  • kellyperlman
  • Ed Kislauskis
  • larryhbern
  • Madison Davis
  • marzankhan
  • megbaker58
  • ofermar2020
  • Dr. Pati
  • pkandala
  • ritusaxena
  • Rick Mandahl
  • sjwilliamspa
  • Srinivas Sriram
  • stuartlpbi
  • Dr. Sudipta Saha
  • tildabarliya
  • vaishnavee24
  • zraviv06
  • zs22